Medications work for severely addicted smokers: Implications for addiction therapists and primary care physicians☆☆☆
Received 13 January 2005; received in revised form 13 January 2005; accepted 13 January 2005.
No abstract is available. To read the body of this article, please view the Full Text online.
aJohns Hopkins University School of Medicine and Pinney Associates, Inc., 3 Bethesda Metro Center, Suite 1400, Bethesda, MD 20814, USA
bTreatment Research Institute and University of Pennsylvania School of Medicine, 600 Public Ledger Boulevard, 150 S. Independence Mall, West Philadelphia, PA 19106, USA
☆ The preparation of this commentary was supported by the Robert Wood Johnson Foundation Innovators Combating Substance Abuse Awards program at Johns Hopkins University School of Medicine.
☆☆ Dr. Henningfield provides consulting services regarding treatments for tobacco dependence to GlaxoSmithKline Consumer Health Care through Pinney Associates. He also has a financial interest in a nicotine replacement product under development, and serves as an expert witness in litigation against the tobacco industry by the United States. Dr. McLellan provides consulting services regarding treatments for opiate dependence to Purdue Pharma Inc. and regarding alcohol treatments to Alkermes Inc.
